- 全部删除
- 您的购物车当前为空
(±)13(14)-DiHDPA is a metabolite of docosahexaenoic acid that is produced via oxidation by cytochrome P450 epoxygenases. Epoxygenase metabolites of DHA, including (±)13(14)-DiHDPA, are reported to inhibit angiogenesis, tumor growth, and metastasis.
(±)13(14)-DiHDPA is a metabolite of docosahexaenoic acid that is produced via oxidation by cytochrome P450 epoxygenases. Epoxygenase metabolites of DHA, including (±)13(14)-DiHDPA, are reported to inhibit angiogenesis, tumor growth, and metastasis.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
50 μg | 待估 | 35日内发货 | |
100 μg | 待估 | 35日内发货 | |
500 μg | 待估 | 35日内发货 | |
1 mg | 待估 | 35日内发货 |
(±)13(14)-DiHDPA 相关产品
产品描述 | (±)13(14)-DiHDPA is a metabolite of docosahexaenoic acid that is produced via oxidation by cytochrome P450 epoxygenases. Epoxygenase metabolites of DHA, including (±)13(14)-DiHDPA, are reported to inhibit angiogenesis, tumor growth, and metastasis. |
分子量 | 362.51 |
分子式 | C22H34O4 |
CAS No. | 1345275-24-2 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
溶解度信息 | Ethanol: 50 mg/mL (137.93 mM), Sonication is recommended. DMF: 50 mg/mL (137.93 mM), Sonication is recommended. PBS (pH 7.2): 0.25 mg/mL (0.69 mM), Sonication is recommended. DMSO: 50 mg/mL (137.93 mM), Sonication is recommended. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容